Erratum to updated survival outcomes and analysis of long-term survivors from the MORE study on safety and efficacy of radioembolization in patients with unresectable colorectal cancer liver metastases
Erratum

Erratum to updated survival outcomes and analysis of long-term survivors from the MORE study on safety and efficacy of radioembolization in patients with unresectable colorectal cancer liver metastases

Andrew Kennedy1, Michael Cohn2, Douglas M. Coldwell3, Alain Drooz4, Eduardo Ehrenwald5, Adeel Kaiser6, Charles W. Nutting7, Steven C. Rose8, Eric A. Wang9, Michael A. Savin10

1Department of Radiation Oncology, Sarah Cannon Research Institute, Nashville, TN, USA; 2Radiology Associates of Hollywood, Pembroke Pines, FL, USA; 3James Graham Brown Cancer Center, University of Louisville, Louisville, KY, USA; 4Fairfax Radiological Consultants, Fairfax, VA, USA; 5Abbott Northwestern Hospital, Minneapolis, MN, USA; 6University of Maryland Medical Center, Baltimore, MD, USA; 7Radiology Imaging Associates, Englewood, CO, USA; 8University of California, San Diego Moores Cancer Center, La Jolla, CA, USA; 9Charlotte Radiology, Charlotte, NC, USA; 10Oakland University William Beaumont School of Medicine, Royal Oak, MI, USA


doi: 10.21037/jgo.2018.03.12


Erratum to: J Gastrointest Oncol 2017;8:614-624

Updated survival outcomes and analysis of long-term survivors from the MORE study on safety and efficacy of radioembolization in patients with unresectable colorectal cancer liver metastases

In the article that appears on page 616, Vol 8, No 4 (August 2017) of the Journal of Gastrointestinal Oncology (JGO) (1), there are some mistakes in the presented box 1.

The sentence “A subgroup analysis of patients >70 years…” should be revised to “A subgroup analysis of patients ≥70 years…”. Also, the correct last sentence should be “Lung shunt fraction (LSF) >10% was predictive of significantly decreased patient survival time compared to LSF ≤10% (median survival, 6.9 vs. 10.0 months; hazard ratio, 1.60; P<0.001) (14)”

The correct box 1 is listed below.

Box 1 Key prior findings from the Metastatic colorectal cancer liver metastases Outcomes after RadioEmbolization (MORE) Study
Full table

The publisher regrets the error.


References

  1. Kennedy A, Cohn M, Coldwell DM, et al. Updated survival outcomes and analysis of long-term survivors from the MORE study on safety and efficacy of radioembolization in patients with unresectable colorectal cancer liver metastases. J Gastrointest Oncol 2017;8:614-24. [Crossref] [PubMed]
Cite this article as: Kennedy A, Cohn M, Coldwell DM, Drooz A, Ehrenwald E, Kaiser A, Nutting CW, Rose SC, Wang EA, Savin MA. Erratum to updated survival outcomes and analysis of long-term survivors from the MORE study on safety and efficacy of radioembolization in patients with unresectable colorectal cancer liver metastases. J Gastrointest Oncol 2018;9(2):E13-E14. doi: 10.21037/jgo.2018.03.12